Cell Therapeutics announces latest trial results for Zevalin

01/22/2009 | RTT News

Patients with mucosa-associated lymphoid tissue lymphoma and low-grade follicular lymphoma in conjunctiva exhibited an 83% complete response rate to Zevalin, Cell Therapeutics' radioimmunotherapy, during a front-line study. The results show that Zevalin could be a good alternative to current treatments, providing lower ocular toxicity and equal or better disease control, said the company's chief medical officer.

View Full Article in:

RTT News

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Systems Test - V&V Engineer - 14000008LS
Abbott
San Jose, CA
Associate - Food and Drug
Keller and Heckman LLP
Washington, DC
Health Care Exchange Account Manager
Kaiser Permanente
San Diego, CA
Area Reimbursement Manager (CT, MA, MD, ME, NH, NJ, NY, PA, VT)
SI-BONE, INC
Multiple Locations, SL_Multiple Locations
Director, Antibiotics and Innovation Project
The Pew Charitable Trusts
Washington, DC